LiFE | Literature for ENYGO

[1]  Junjun Yang,et al.  Primary treatment of stage IV gestational trophoblastic neoplasia with floxuridine, dactinomycin, etoposide and vincristine (FAEV): A report based on our 10-year clinical experiences. , 2016, Gynecologic oncology.

[2]  R. Berkowitz,et al.  Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. , 2016, American journal of obstetrics and gynecology.

[3]  D. Vinatier,et al.  SALL4 expression in gestational trophoblastic tumors: a useful tool to distinguish choriocarcinoma from placental site trophoblastic tumor and epithelioid trophoblastic tumor. , 2016, Human pathology.

[4]  A. Gadducci,et al.  Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. , 2016, Anticancer research.

[5]  A. Schott,et al.  Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone. , 2016, American journal of obstetrics and gynecology.

[6]  J. Yang,et al.  Placental site trophoblastic tumor: A review of 108 cases and their implications for prognosis and treatment. , 2016, Gynecologic oncology.

[7]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[8]  P. Liu,et al.  Clinical characteristics and prognosis of 272 postterm choriocarcinoma patients at Peking Union Medical College Hospital: a retrospective cohort study , 2016, BMC Cancer.

[9]  J. Pfeifer,et al.  Use of short tandem repeat analysis in unusual presentations of trophoblastic tumors and their mimics. , 2016, Human pathology.

[10]  N. Sebire,et al.  Intraplacental choriocarcinoma: Systematic review and management guidance. , 2016, Gynecologic oncology.

[11]  R. Berkowitz,et al.  Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women , 2016, International Journal of Gynecologic Cancer.

[12]  A. Soriano-Estrella,et al.  Etoposide-Actinomycin as Salvage Regimen for the Treatment of Nonmetastatic and Low-Risk Metastatic Gestational Trophoblastic Neoplasia: Experience at the Philippine General Hospital , 2016, International Journal of Gynecologic Cancer.

[13]  M. Seckl,et al.  Late spontaneous resolution of persistent molar pregnancy , 2016, BJOG : an international journal of obstetrics and gynaecology.

[14]  R. Kuick,et al.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.

[15]  Ping Wang,et al.  miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint , 2016, Nature Communications.

[16]  M. Seckl,et al.  Anti-Müllerian Hormone in Patients Treated with Chemotherapy for Gestational Trophoblastic Neoplasia Does Not Predict Short-Term Fertility. , 2016, The Journal of reproductive medicine.

[17]  A. Santin,et al.  Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers , 2016, Expert opinion on biological therapy.

[18]  Cai-yun Zhou,et al.  Immunohistochemical Expression and Clinical Significance of Wnt11 and BCL2A1 in Complete Moles. , 2016, Analytical and quantitative cytopathology and histopathology.

[19]  T. Colgan,et al.  A Reappraisal of the Incidence of Placental Hydatidiform Mole Using Selective Molecular Genotyping , 2016, International Journal of Gynecologic Cancer.

[20]  L. Hutchins,et al.  Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination , 2016, Cancer Immunology, Immunotherapy.

[21]  T. Wu,et al.  Current state in the development of candidate therapeutic HPV vaccines , 2016, Expert review of vaccines.

[22]  Yu Wang,et al.  Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia , 2016, Journal of chemotherapy.

[23]  R. Berkowitz,et al.  The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. , 2016, Gynecologic oncology.

[24]  A. Schott,et al.  Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13. , 2016, American journal of obstetrics and gynecology.

[25]  X. Qian,et al.  Long‐term outcome of patients with persistent low‐level elevation of human chorionic gonadotrophin , 2016, The journal of obstetrics and gynaecology research.

[26]  Y. Zhang,et al.  Young Cervical Cancer Patients May Be More Responsive than Older Patients to Neoadjuvant Chemotherapy Followed by Radical Surgery , 2016, PloS one.

[27]  M. Picchio,et al.  [¹⁸F]fluorodeoxyglucose positron emission tomography/computed tomography and trophoblastic disease: the gynecologist perspective. , 2016, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[28]  M. Saidani,et al.  Endometrial cancer in elderly women: Which disease, which surgical management? A systematic review of the literature. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  L. Sunde,et al.  A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group , 2016, Acta oncologica.

[30]  T. Wu,et al.  A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). , 2016, Gynecologic oncology.

[31]  S. H. van der Burg,et al.  Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response , 2016, Clinical Cancer Research.

[32]  E. Cavalier,et al.  Persistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease , 2016, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[33]  N. Bickell,et al.  Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995–2008 , 2016, Obstetrics and gynecology.

[34]  F. Sweep,et al.  Trends in incidence for gestational trophoblastic disease over the last 20 years in a population-based study. , 2016, Gynecologic oncology.

[35]  R. Angioli,et al.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program , 2016, Tumor Biology.

[36]  A. Fyles,et al.  Association between Metformin Use and Mortality after Cervical Cancer in Older Women with Diabetes , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[37]  Rossella Di Pierro,et al.  [Gestational Trophoblastic Disease: psychological impact and the role of defence mechanisms during illness and follow-up]. , 2015, Recenti progressi in medicina.

[38]  L. Elit,et al.  Recommendations for Follow-up Care for Gynecologic Cancer Survivors. , 2015, Obstetrics and gynecology.

[39]  H. Matsui,et al.  Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia. , 2015, Gynecologic oncology.

[40]  Yinfeng Wang,et al.  Medical termination of a partial hydatidiform mole and coexisting fetus during the second trimester: A case report. , 2015, Oncology letters.

[41]  R. Francisco,et al.  Is Doppler ultrasound useful for evaluating gestational trophoblastic disease? , 2015, Clinics.

[42]  Mei Peng,et al.  Tegafur Substitution for 5-Fu in Combination with Actinomycin D to Treat Gestational Trophoblastic Neoplasm , 2015, PloS one.

[43]  A. Ben-Haroush,et al.  Endometrial Cancer Surgery for Elderly Women—The Early Postoperative Period , 2015, International Journal of Gynecologic Cancer.

[44]  Kathy L. MacLaughlin,et al.  Surveillance and Care of the Gynecologic Cancer Survivor , 2015, Journal of women's health.

[45]  E. Ko,et al.  Adjuvant Treatment and Clinical Trials in Elderly Patients With Endometrial Cancer: A Time for Change? , 2015, International Journal of Gynecologic Cancer.

[46]  Yuxin Tang,et al.  An invasive mole with bilateral kidney metastases: A case report , 2015, Oncology letters.

[47]  Eva Pagano,et al.  Economic Considerations on the Follow-Up Practice in Gynecologic Cancers: Few Lights and Many Shadows From a Literature Review , 2015, International Journal of Gynecologic Cancer.

[48]  D. Cibula,et al.  Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses? , 2015, Current Oncology Reports.

[49]  V. Bae-Jump,et al.  Comprehensive care in gynecologic oncology: The importance of palliative care. , 2015, Gynecologic oncology.

[50]  G. Kotronoulas,et al.  A systematic review of the supportive care needs of women living with and beyond cervical cancer. , 2015, Gynecologic oncology.

[51]  X. Wang,et al.  Cancer-related and treatment-related fatigue. , 2015, Gynecologic oncology.

[52]  S. Vesely,et al.  Central nervous system metastasis in gynecologic cancer: symptom management, prognosis and palliative management strategies. , 2015, Gynecologic oncology.

[53]  J. Dimopoulos,et al.  Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. , 2015, Gynecologic oncology.

[54]  O. Ortmann,et al.  Invasive mole in a perimenopausal woman: a case report and systematic review , 2014, Archives of Gynecology and Obstetrics.

[55]  Monika Janda,et al.  Incidence, risk factors and estimates of a woman's risk of developing secondary lower limb lymphedema and lymphedema-specific supportive care needs in women treated for endometrial cancer. , 2015, Gynecologic oncology.

[56]  K. Charoenkwan,et al.  Outcome of the Gynecologic Oncology Patients Surveillance Network Program. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[57]  P. Novotny,et al.  Disease-free ovarian cancer patients report severe pain and fatigue over time: prospective quality of life assessment in a consecutive series. , 2015, European journal of gynaecological oncology.

[58]  W. Cheung,et al.  Follow-up patterns of cancer survivors: a survey of Canadian radiation oncologists , 2015, Journal of Cancer Survivorship.

[59]  V. Beesley,et al.  Prevalence, predictors, and correlates of supportive care needs among women 3–5 years after a diagnosis of endometrial cancer , 2015, Supportive Care in Cancer.

[60]  Jun Tian,et al.  Sleep status of cervical cancer patients and predictors of poor sleep quality during adjuvant therapy , 2015, Supportive Care in Cancer.

[61]  J. Walkowiak,et al.  Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer , 2015, Supportive Care in Cancer.

[62]  R. M. Bakker,et al.  Psychosexual support for gynecological cancer survivors: professionals’ current practices and need for assistance , 2015, Supportive Care in Cancer.

[63]  J. Sheeder,et al.  Comparative Outcomes in Older and Younger Women Undergoing Laparotomy or Robotic Surgical Staging for Endometrial Cancer , 2014 .

[64]  M. Andrykowski.  Addressing anxiety and insecure attachment in close relationships could improve quality of life for gynaecological cancer survivors , 2014, Evidence-Based Nursing.

[65]  A. Reuss,et al.  Quality of life and sexual function in patients with borderline tumors of the ovary. A substudy of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group ROBOT study , 2014, Supportive Care in Cancer.

[66]  T. Lawrie,et al.  Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. , 2012, The Cochrane database of systematic reviews.